Return to homepagePandemic Pact

Hydroxychloroquine shortages in Canada [Funder: Singer Family Fund for SLE research]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Evelyne Vinet, Arielle Mendel

  • Research Location

    Canada

  • Lead Research Institution

    Research Institute of McGill University Health Centre

  • Research Priority Alignment

    N/A

  • Research Category

    Health Systems Research

  • Research Subcategory

    Medicines, vaccines & other technologies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Hydroxychloroquine is currently being investigated for its benefit in COVID19 infection. This drug is a cornerstone treatment for severe chronic rheumatic diseases including systemic lupus (SLE) a potentially life-threatening condition affecting thousands of Canadians from every stage of life. Interruption of treatment places these already vulnerable individuals at great risk for disease flares and major health complications. Policies recently put in place have already caused difficulties with hydroxychloroquine across many jurisdictions including Canada. Our project will survey Canadian rheumatologists to identify how many patients have already been affected by these issues.